share_log

Vivos Therapeutics | 8-K: Current report

Vivos Therapeutics | 8-K: Current report

Vivos Therapeutics | 8-K：重大事件
美股sec公告 ·  06/25 16:36
Moomoo AI 已提取核心信息
Vivos Therapeutics, Inc., a Delaware-incorporated company listed on The Nasdaq Stock Market under the trading symbol VVOS, has filed a Current Report on Form 8-K with the SEC on June 25, 2024. The report addresses the company's non-compliance with Nasdaq's Listing Rule 5550(b)(1) regarding the minimum stockholders' equity of $2.5 million as of March 31, 2024. Following a $7.5 million private placement completed on June 10, 2024, Vivos Therapeutics believes it now meets the equity requirement. A hearing with a Nasdaq Hearings Panel is scheduled for June 27, 2024, where the company will present its case for continued listing on Nasdaq. The decision from the Panel is expected within 30 days of the hearing. The company acknowledges the risk of being unable to raise sufficient capital to maintain compliance with the Equity Requirement, which could lead to delisting from Nasdaq and have a material adverse effect on the company's operations and stock price.
Vivos Therapeutics, Inc., a Delaware-incorporated company listed on The Nasdaq Stock Market under the trading symbol VVOS, has filed a Current Report on Form 8-K with the SEC on June 25, 2024. The report addresses the company's non-compliance with Nasdaq's Listing Rule 5550(b)(1) regarding the minimum stockholders' equity of $2.5 million as of March 31, 2024. Following a $7.5 million private placement completed on June 10, 2024, Vivos Therapeutics believes it now meets the equity requirement. A hearing with a Nasdaq Hearings Panel is scheduled for June 27, 2024, where the company will present its case for continued listing on Nasdaq. The decision from the Panel is expected within 30 days of the hearing. The company acknowledges the risk of being unable to raise sufficient capital to maintain compliance with the Equity Requirement, which could lead to delisting from Nasdaq and have a material adverse effect on the company's operations and stock price.
纳斯达克股票代码VVOS的特拉华州公司Vivos Therapeutics已于2024年6月25日向美国证券交易委员会提交了《8-K表格的最新报告书》。该报告涉及公司未能符合纳斯达克5550(b)(1)号上市规则的最低股东权益要求，即截至2024年3月31日的股东权益要求为250万美元。在2024年6月10日完成的750万美元定向增发后，Vivos Therapeutics认为自己现在符合股权要求。纳斯达克听证会定于2024年6月27日举行，届时公司将为继续在纳斯达克上市作出辩词。面板的决定预计将在听证会后30天内公布。公司认识到无法筹集足够的资本以满足股权要求的风险，这可能导致公司被纳斯达克摘牌并对其运营和股价产生实质性不利影响。
纳斯达克股票代码VVOS的特拉华州公司Vivos Therapeutics已于2024年6月25日向美国证券交易委员会提交了《8-K表格的最新报告书》。该报告涉及公司未能符合纳斯达克5550(b)(1)号上市规则的最低股东权益要求，即截至2024年3月31日的股东权益要求为250万美元。在2024年6月10日完成的750万美元定向增发后，Vivos Therapeutics认为自己现在符合股权要求。纳斯达克听证会定于2024年6月27日举行，届时公司将为继续在纳斯达克上市作出辩词。面板的决定预计将在听证会后30天内公布。公司认识到无法筹集足够的资本以满足股权要求的风险，这可能导致公司被纳斯达克摘牌并对其运营和股价产生实质性不利影响。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息